An NSAID formulated to penetrate target ocular tissues
PROLENSA
®
POWERED FOR PENETRATION
Available in a 3-mL bottle size
PROLENSA
®
delivers potency and corneal penetration with QD efficacy
1,2
•
Advanced formulation delivers corneal penetration
1-3
•
Proven efficacy at a low concentration
1,4
INDICATIONS AND USAGE
PROLENSA
®
(bromfenac ophthalmic solution) 0.07% is a nonsteroidal
anti-inflammatory drug (NSAID) indicated for the treatment of postoperative
inflammation and reduction of ocular pain in patients who have undergone
cataract surgery.
IMPORTANT SAFETY INFORMATION ABOUT PROLENSA
®
Warnings and Precautions
•
Sulfite allergic reactions
•
Slow or delayed healing
•
Potential for cross-sensitivity
•
Increased bleeding of ocular tissues
•
Corneal effects, including keratitis
•
Contact lens wear
Adverse Reactions
The most commonly reported adverse
reactions in 3%-8% of patients were
anterior chamber inflammation, foreign
body sensation, eye pain, photophobia,
and blurred vision.
Please see brief summary of full Prescribing Information on adjacent page.
References: 1. PROLENSA
®
Prescribing Information, April 2013. 2. Data on file, Bausch & Lomb Incorporated.
3. Baklayan GA, Patterson HM, Song CK, Gow JA, McNamara TR. 24-hour evaluation of the ocular distribution of
14
C-labeled
bromfenac following topical instillation into the eyes of New Zealand White rabbits. J Ocul Pharmacol Ther. 2008;24(4):392-398.
4. BROMDAY
®
Prescribing Information, October 2012.
PROLENSA is a registered trademark of Bausch & Lomb Incorporated or its affiliates.
© Bausch & Lomb Incorporated. US/PRA/14/0043
